(Q36600294)

15 August 2017

1 reference

title

Investigating mammalian target of rapamycin inhibitors for their anticancer properties (English)

1 reference

15 August 2017

1 reference

1

Piotr Smolewski

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

Expert Opinion on Investigational Drugs

15 August 2017

published in

1 reference

15 August 2017

volume

15

1 reference

15 August 2017

issue

10

1 reference

15 August 2017

page(s)

1201-1227

1 reference

mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Regulation of cap-dependent translation by eIF4E inhibitory proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Regulation and role of autophagy in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

HEAT repeats in the Huntington's disease protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Molecular organization of target of rapamycin complex 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

TSC2: filling the GAP in the mTOR signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

TSC2 mediates cellular energy response to control cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Rheb binds and regulates the mTOR kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

The NF1 tumor suppressor critically regulates TSC2 and mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Key cancer cell signal transduction pathways as therapeutic targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

The LKB1 tumor suppressor negatively regulates mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Growth control under stress: mTOR regulation through the REDD1-TSC pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

The coordinate regulation of the p53 and mTOR pathways in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Rheb promotes cell growth as a component of the insulin/TOR signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

The solution structure of the FATC domain of the protein kinase target of rapamycin suggests a role for redox-dependent structural and cellular stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Regulation of cell migration by the C2 domain of the tumor suppressor PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

S6 kinase 2 potentiates interleukin-3-driven cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

eIF4E expression in tumors: its possible role in progression of malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

eIF-4E expression and its role in malignancies and metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Expression of constitutively active 4EBP-1 enhances p27Kip1 expression and inhibits proliferation of MCF7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Perturbations of the AKT signaling pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Survival of acute myeloid leukemia cells requires PI3 kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Negative regulation of melanogenesis by phospholipase D1 through mTOR/p70 S6 kinase 1 signaling in mouse B16 melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Targeting the molecular target of rapamycin (mTOR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Akt-dependent cell size regulation by the adhesion molecule on glia occurs independently of phosphatidylinositol 3-kinase and Rheb signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

mTOR regulates cell survival after etoposide treatment in primary AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Final height after transplantation in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Enhanced radiation damage of tumor vasculature by mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Radiotherapy and Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Cyclotherapy: protection of normal cells and unshielding of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Rapamycin resistance tied to defective regulation of p27Kip1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1201

10.1517/13543784.15.10.1201

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference